Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01198808|
Recruitment Status : Unknown
Verified January 2012 by Technische Universität München.
Recruitment status was: Active, not recruiting
First Posted : September 10, 2010
Last Update Posted : January 18, 2012
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy.
It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||December 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01198808
|Urologische Klinik der Technischen Universität München|
|Munich, Bavaria, Germany, 81675|
|Principal Investigator:||Thomas Horn, MD||Department of Urology, Technische Universität München|